[
  {
    "ts": null,
    "headline": "Eli Lilly to Build $6 Billion Alabama Plant as Part of U.S. Investment",
    "summary": "The site is the third of four new facilities in the U.S. that the pharmaceutical company plans to announce, Eli Lilly said.",
    "url": "https://finnhub.io/api/news?id=3deb6543baddbc662cf7970e3452180b3f246e746630e6072a74c984055ab900",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765313940,
      "headline": "Eli Lilly to Build $6 Billion Alabama Plant as Part of U.S. Investment",
      "id": 137749829,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The site is the third of four new facilities in the U.S. that the pharmaceutical company plans to announce, Eli Lilly said.",
      "url": "https://finnhub.io/api/news?id=3deb6543baddbc662cf7970e3452180b3f246e746630e6072a74c984055ab900"
    }
  },
  {
    "ts": null,
    "headline": "Lilly to build $6 billion facility to manufacture active pharmaceutical ingredients in Alabama",
    "summary": "Eli Lilly and Company (NYSE: LLY) today announced plans to invest more than $6 billion in a new manufacturing facility in Huntsville, Alabama. This next-generation synthetic medicine active pharmaceutical ingredient (API) facility, the third of four new U.S. sites Lilly plans to announce, will produce small molecule synthetic and peptide medicines.",
    "url": "https://finnhub.io/api/news?id=8fc6f755817cb7d9eb3fe61a6e9b4de2d429346cc9ee01f689c4536c6927c323",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765312200,
      "headline": "Lilly to build $6 billion facility to manufacture active pharmaceutical ingredients in Alabama",
      "id": 137749830,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly and Company (NYSE: LLY) today announced plans to invest more than $6 billion in a new manufacturing facility in Huntsville, Alabama. This next-generation synthetic medicine active pharmaceutical ingredient (API) facility, the third of four new U.S. sites Lilly plans to announce, will produce small molecule synthetic and peptide medicines.",
      "url": "https://finnhub.io/api/news?id=8fc6f755817cb7d9eb3fe61a6e9b4de2d429346cc9ee01f689c4536c6927c323"
    }
  },
  {
    "ts": null,
    "headline": "Amid Escalating Market Investment, Physicians Forecast Rapid Uptake of Oral Semaglutide Upon Approval in Obesity, According to Spherix Global Insights",
    "summary": "US primary care physicians and endocrinologists indicate strong intent to prescribe oral semaglutide for weight loss, despite relatively low pre-approval awareness.EXTON, PA, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Public interest in obesity treatments continues to intensify, driving unprecedented momentum across an increasingly competitive therapeutic landscape. In November, the FDA granted National Priority Vouchers, and thus expedited review, to Eli Lilly’s orforglipron and a high-dose formulation",
    "url": "https://finnhub.io/api/news?id=42c8ca781428d3dcd9496a2a062b50158ee9c46d7e31ec602275e310164313fe",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765309440,
      "headline": "Amid Escalating Market Investment, Physicians Forecast Rapid Uptake of Oral Semaglutide Upon Approval in Obesity, According to Spherix Global Insights",
      "id": 137749831,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "US primary care physicians and endocrinologists indicate strong intent to prescribe oral semaglutide for weight loss, despite relatively low pre-approval awareness.EXTON, PA, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Public interest in obesity treatments continues to intensify, driving unprecedented momentum across an increasingly competitive therapeutic landscape. In November, the FDA granted National Priority Vouchers, and thus expedited review, to Eli Lilly’s orforglipron and a high-dose formulation",
      "url": "https://finnhub.io/api/news?id=42c8ca781428d3dcd9496a2a062b50158ee9c46d7e31ec602275e310164313fe"
    }
  },
  {
    "ts": null,
    "headline": "Pharma ETFs to Gain From Landmark UK-US Zero-Tariff Deal",
    "summary": "Pharma ETFs like IHE are poised to surge as the UK-US zero-tariff deal raises UK drug prices and strengthens major U.S. players' outlook.",
    "url": "https://finnhub.io/api/news?id=18c6c518fd9ae16d7e56818f8e62791ae026a9ff69d57b0ee4933283232cc6a8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765305600,
      "headline": "Pharma ETFs to Gain From Landmark UK-US Zero-Tariff Deal",
      "id": 137749832,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Pharma ETFs like IHE are poised to surge as the UK-US zero-tariff deal raises UK drug prices and strengthens major U.S. players' outlook.",
      "url": "https://finnhub.io/api/news?id=18c6c518fd9ae16d7e56818f8e62791ae026a9ff69d57b0ee4933283232cc6a8"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Expands Obesity Pipeline With Up to $2.1 Billion Deal for YaoPharma Pill",
    "summary": "Agreement deepens company's push into fast-growing weight-loss market",
    "url": "https://finnhub.io/api/news?id=3744d48e378f60ff86de073952ace1f6ad4ba70ce9260040b2d3200590c4d7f8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765301402,
      "headline": "Pfizer Expands Obesity Pipeline With Up to $2.1 Billion Deal for YaoPharma Pill",
      "id": 137742557,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Agreement deepens company's push into fast-growing weight-loss market",
      "url": "https://finnhub.io/api/news?id=3744d48e378f60ff86de073952ace1f6ad4ba70ce9260040b2d3200590c4d7f8"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Turns to China for Trial Weight Loss Drug. Congress Is Worried About Chinese Biotechs.",
    "summary": "Big American drugmakers are hunting for novel weight loss drugs in the labs of China’s biotech industry, while U.S. authorities try to undercut the growing Chinese biotech sector.",
    "url": "https://finnhub.io/api/news?id=78c46051a4119b40bfcaee2524a60fec30a54ecbb5097ba53ab055009cf40c50",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765299000,
      "headline": "Pfizer Turns to China for Trial Weight Loss Drug. Congress Is Worried About Chinese Biotechs.",
      "id": 137742558,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Big American drugmakers are hunting for novel weight loss drugs in the labs of China’s biotech industry, while U.S. authorities try to undercut the growing Chinese biotech sector.",
      "url": "https://finnhub.io/api/news?id=78c46051a4119b40bfcaee2524a60fec30a54ecbb5097ba53ab055009cf40c50"
    }
  },
  {
    "ts": null,
    "headline": "Cramer Loves These Dividend Stocks",
    "summary": "Jim Cramer, the charismatic host of CNBC’s Mad Money, has become a household name for investors seeking bold, actionable insights. Known for his high-energy delivery and colorful metaphors, Cramer blends deep market knowledge with an ability to distill complex financial trends into digestible advice. While he doesn’t exclusively focus on dividend stocks, his analysis often ... Cramer Loves These Dividend Stocks",
    "url": "https://finnhub.io/api/news?id=4d3d25825db582b8ef31920cfcf093f0bb3ff893625601daad9a9dd5ec82b8c3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765297177,
      "headline": "Cramer Loves These Dividend Stocks",
      "id": 137742559,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Jim Cramer, the charismatic host of CNBC’s Mad Money, has become a household name for investors seeking bold, actionable insights. Known for his high-energy delivery and colorful metaphors, Cramer blends deep market knowledge with an ability to distill complex financial trends into digestible advice. While he doesn’t exclusively focus on dividend stocks, his analysis often ... Cramer Loves These Dividend Stocks",
      "url": "https://finnhub.io/api/news?id=4d3d25825db582b8ef31920cfcf093f0bb3ff893625601daad9a9dd5ec82b8c3"
    }
  },
  {
    "ts": null,
    "headline": "1 Major Factor Behind the Healthcare Sector's Recent Surge",
    "summary": "Blockbuster drugs are a major driver of the growth of healthcare stocks.",
    "url": "https://finnhub.io/api/news?id=961fc079ac660d5adfeab69920ace9a1d553cc860668ba87c4183f0a08ab4342",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765296917,
      "headline": "1 Major Factor Behind the Healthcare Sector's Recent Surge",
      "id": 137741749,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Blockbuster drugs are a major driver of the growth of healthcare stocks.",
      "url": "https://finnhub.io/api/news?id=961fc079ac660d5adfeab69920ace9a1d553cc860668ba87c4183f0a08ab4342"
    }
  },
  {
    "ts": null,
    "headline": "In The 'Uber Bull' Biotech Market, Is Structure The Next Metsera?",
    "summary": "In a post-Metsera world, Structure Therapeutics could be the next big takeover candidate, analysts said Tuesday.",
    "url": "https://finnhub.io/api/news?id=8d87d77ff69a12b94520f460402b6929bfba63b3e41db2aaf5b1aa17e8ec0381",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765296676,
      "headline": "In The 'Uber Bull' Biotech Market, Is Structure The Next Metsera?",
      "id": 137742561,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "In a post-Metsera world, Structure Therapeutics could be the next big takeover candidate, analysts said Tuesday.",
      "url": "https://finnhub.io/api/news?id=8d87d77ff69a12b94520f460402b6929bfba63b3e41db2aaf5b1aa17e8ec0381"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly to build $6 billion manufacturing plant in Alabama to help make upcoming obesity pill, other drugs",
    "summary": "That added production capacity for Eli Lilly's obesity pill, orforglipron, is crucial as the company races to file for its approval.",
    "url": "https://finnhub.io/api/news?id=d7cf84e51b4fe78c34599c6ea15434c51089081eb44d4291a7b0f9bce4b98441",
    "source": "CNBC",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765294201,
      "headline": "Eli Lilly to build $6 billion manufacturing plant in Alabama to help make upcoming obesity pill, other drugs",
      "id": 137748294,
      "image": "https://image.cnbcfm.com/api/v1/image/108203224-1758715854126-gettyimages-2237030698-hc091925lillypharmaplant1.jpeg?v=1758715935&w=1920&h=1080",
      "related": "LLY",
      "source": "CNBC",
      "summary": "That added production capacity for Eli Lilly's obesity pill, orforglipron, is crucial as the company races to file for its approval. ",
      "url": "https://finnhub.io/api/news?id=d7cf84e51b4fe78c34599c6ea15434c51089081eb44d4291a7b0f9bce4b98441"
    }
  },
  {
    "ts": null,
    "headline": "GPCR Stock Soars 102% on Strong Phase II Obesity Data for Aleniglipron",
    "summary": "Structure Therapeutics jumps after phase II data show aleniglipron delivering strong, durable weight-loss results across multiple studies.",
    "url": "https://finnhub.io/api/news?id=eff78715fe9e9042f631c351d4d7358d5b49c96fb6b8aef813062bbb8543db81",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765290420,
      "headline": "GPCR Stock Soars 102% on Strong Phase II Obesity Data for Aleniglipron",
      "id": 137742562,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Structure Therapeutics jumps after phase II data show aleniglipron delivering strong, durable weight-loss results across multiple studies.",
      "url": "https://finnhub.io/api/news?id=eff78715fe9e9042f631c351d4d7358d5b49c96fb6b8aef813062bbb8543db81"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly and Company (LLY) Is a Trending Stock: Facts to Know Before Betting on It",
    "summary": "Lilly (LLY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.",
    "url": "https://finnhub.io/api/news?id=0996aaec7650e67eecfbdfe104f5346c9b24374bb2e44c7cabe050f2088c53f5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765288806,
      "headline": "Eli Lilly and Company (LLY) Is a Trending Stock: Facts to Know Before Betting on It",
      "id": 137742563,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Lilly (LLY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.",
      "url": "https://finnhub.io/api/news?id=0996aaec7650e67eecfbdfe104f5346c9b24374bb2e44c7cabe050f2088c53f5"
    }
  },
  {
    "ts": null,
    "headline": "Lilly and Adverum announce expiration and completion of Adverum tender offer and acquisition",
    "summary": "Eli Lilly and Company (NYSE: LLY) and Adverum Biotechnologies, Inc. (NASDAQ: ADVM) today announced that the tender offer (the \"Offer\") by Flying Tigers Acquisition Corporation (\"Purchaser\"), a direct wholly-owned subsidiary of Lilly, to purchase all of the issued and outstanding shares (\"Shares\") of Adverum's common stock in exchange for (i) $3.56 per Share, net to the stockholder in cash, without interest and less any applicable tax withholding, plus (ii) one non-tradable contingent value right",
    "url": "https://finnhub.io/api/news?id=01181dcf8776eae01fcece445e9f1a4d36a06b7264aa05f0a39f27ffa3e28855",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765286880,
      "headline": "Lilly and Adverum announce expiration and completion of Adverum tender offer and acquisition",
      "id": 137740090,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly and Company (NYSE: LLY) and Adverum Biotechnologies, Inc. (NASDAQ: ADVM) today announced that the tender offer (the \"Offer\") by Flying Tigers Acquisition Corporation (\"Purchaser\"), a direct wholly-owned subsidiary of Lilly, to purchase all of the issued and outstanding shares (\"Shares\") of Adverum's common stock in exchange for (i) $3.56 per Share, net to the stockholder in cash, without interest and less any applicable tax withholding, plus (ii) one non-tradable contingent value right",
      "url": "https://finnhub.io/api/news?id=01181dcf8776eae01fcece445e9f1a4d36a06b7264aa05f0a39f27ffa3e28855"
    }
  },
  {
    "ts": null,
    "headline": "Ability Biotherapeutics Appoints Angèle Maki, PhD, as Chief Business Officer",
    "summary": "MONTREAL, December 09, 2025--Ability Biotherapeutics, a biotechnology company advancing logic-gated antibody therapies for cancer and autoimmune diseases, today announced the appointment of Angèle Maki, PhD, as Chief Business Officer (CBO).",
    "url": "https://finnhub.io/api/news?id=a7e4d9343a9e5f5495c6c8ca3af18095dc62604cf691f2f06bb802cc1da57cb5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765284300,
      "headline": "Ability Biotherapeutics Appoints Angèle Maki, PhD, as Chief Business Officer",
      "id": 137740091,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "MONTREAL, December 09, 2025--Ability Biotherapeutics, a biotechnology company advancing logic-gated antibody therapies for cancer and autoimmune diseases, today announced the appointment of Angèle Maki, PhD, as Chief Business Officer (CBO).",
      "url": "https://finnhub.io/api/news?id=a7e4d9343a9e5f5495c6c8ca3af18095dc62604cf691f2f06bb802cc1da57cb5"
    }
  },
  {
    "ts": null,
    "headline": "Lilly's Jaypirca (pirtobrutinib) significantly improved progression-free survival, reducing the risk of progression or death by 80%, versus chemoimmunotherapy in patients with treatment-naïve CLL/SLL",
    "summary": "Eli Lilly and Company (NYSE: LLY) today announced results from the Phase 3 BRUIN CLL-313 clinical trial of Jaypirca (pirtobrutinib), a non-covalent Bruton tyrosine kinase (BTK) inhibitor, versus bendamustine plus rituximab (BR), in treatment-naïve patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) without 17p deletions. Pirtobrutinib met its primary endpoint demonstrating a reduction in the risk of disease progression or death by 80% (HR=0.20 [95% CI, 0.11-0.37];",
    "url": "https://finnhub.io/api/news?id=379c76e358007a48a040955cf4228d3d58e40ab350ec7ed0a708ac849c6827fe",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765283400,
      "headline": "Lilly's Jaypirca (pirtobrutinib) significantly improved progression-free survival, reducing the risk of progression or death by 80%, versus chemoimmunotherapy in patients with treatment-naïve CLL/SLL",
      "id": 137740092,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly and Company (NYSE: LLY) today announced results from the Phase 3 BRUIN CLL-313 clinical trial of Jaypirca (pirtobrutinib), a non-covalent Bruton tyrosine kinase (BTK) inhibitor, versus bendamustine plus rituximab (BR), in treatment-naïve patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) without 17p deletions. Pirtobrutinib met its primary endpoint demonstrating a reduction in the risk of disease progression or death by 80% (HR=0.20 [95% CI, 0.11-0.37];",
      "url": "https://finnhub.io/api/news?id=379c76e358007a48a040955cf4228d3d58e40ab350ec7ed0a708ac849c6827fe"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer adds to obesity bet with up to $2.1 billion deal to develop Chinese company's pill",
    "summary": "The deal will help Pfizer beef up and diversify its obesity drug pipeline following its $10 billion acquisition of obesity biotech Metsera last month.",
    "url": "https://finnhub.io/api/news?id=b77a324d46c03ec78cb392b377522475833bfdb93c7ce79c18ba6373e432f43a",
    "source": "CNBC",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765278872,
      "headline": "Pfizer adds to obesity bet with up to $2.1 billion deal to develop Chinese company's pill ",
      "id": 137741745,
      "image": "https://image.cnbcfm.com/api/v1/image/107364661-17062120762021-04-23t143705z_84240954_rc2q1n97o4om_rtrmadp_0_health-coronavirus-eu-pfizer.jpeg?v=1706212117&w=1920&h=1080",
      "related": "LLY",
      "source": "CNBC",
      "summary": "The deal will help Pfizer beef up and diversify its obesity drug pipeline following its $10 billion acquisition of obesity biotech Metsera last month. ",
      "url": "https://finnhub.io/api/news?id=b77a324d46c03ec78cb392b377522475833bfdb93c7ce79c18ba6373e432f43a"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer dips into China for another try at an obesity pill",
    "summary": "A potentially $2 billion deal with a subsidiary of Shanghai-based Fosun Pharma gives Pfizer a new chance at an oral weight loss medication, an area where its internal research has struggled.",
    "url": "https://finnhub.io/api/news?id=8947d730aae5319765ae08e2828573983b01007bcf5b7e7e690eb635d706980e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765277940,
      "headline": "Pfizer dips into China for another try at an obesity pill",
      "id": 137742564,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "A potentially $2 billion deal with a subsidiary of Shanghai-based Fosun Pharma gives Pfizer a new chance at an oral weight loss medication, an area where its internal research has struggled.",
      "url": "https://finnhub.io/api/news?id=8947d730aae5319765ae08e2828573983b01007bcf5b7e7e690eb635d706980e"
    }
  },
  {
    "ts": null,
    "headline": "Wall Street Remains Cautious on Molson Coors Beverage Company (TAP)",
    "summary": "Molson Coors Beverage Company (NYSE:TAP) is among the Top 15 Lowest P/E Ratios of the S&P 500 in 2025. On November 21, Piper Sandler lowered its price target for the stock to $50 from $52, while keeping a Neutral rating. The firm said it was revising its price target, taking into account recent developments in […]",
    "url": "https://finnhub.io/api/news?id=cbb618b0e3146cce359d9ebd915b313ac5b152a3ed59a01d9b7f10e3c66a4ecc",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765277625,
      "headline": "Wall Street Remains Cautious on Molson Coors Beverage Company (TAP)",
      "id": 137740093,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Molson Coors Beverage Company (NYSE:TAP) is among the Top 15 Lowest P/E Ratios of the S&P 500 in 2025. On November 21, Piper Sandler lowered its price target for the stock to $50 from $52, while keeping a Neutral rating. The firm said it was revising its price target, taking into account recent developments in […]",
      "url": "https://finnhub.io/api/news?id=cbb618b0e3146cce359d9ebd915b313ac5b152a3ed59a01d9b7f10e3c66a4ecc"
    }
  },
  {
    "ts": null,
    "headline": "Jim Cramer's top 10 things to watch in the stock market Tuesday",
    "summary": "Stocks were little changed early this morning after a down session for Wall Street. Traders are awaiting the Fed's next interest rate decision.",
    "url": "https://finnhub.io/api/news?id=d1e40cbed388b388cf8cf780c69e86c3ba833b8b4b0630810eb03e9017419e58",
    "source": "CNBC",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765269928,
      "headline": "Jim Cramer's top 10 things to watch in the stock market Tuesday",
      "id": 137741601,
      "image": "https://image.cnbcfm.com/api/v1/image/108222121-17623850772025-11-05t230736z_214248853_rc2lqhae98m2_rtrmadp_0_britain-royals-king.jpeg?v=1762385223&w=1920&h=1080",
      "related": "LLY",
      "source": "CNBC",
      "summary": "Stocks were little changed early this morning after a down session for Wall Street. Traders are awaiting the Fed's next interest rate decision.",
      "url": "https://finnhub.io/api/news?id=d1e40cbed388b388cf8cf780c69e86c3ba833b8b4b0630810eb03e9017419e58"
    }
  },
  {
    "ts": null,
    "headline": "How Lilly uses Big Pharma heft to lift up-and-coming biotechs",
    "summary": "With great power comes great responsibility, and Eli Lilly is employing financial success and technical know-how to give smaller biotechs a leg up.",
    "url": "https://finnhub.io/api/news?id=7a6084352316af490fdd6bb1f536884386918294b9cc5d759164bb8ded481e0f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765267200,
      "headline": "How Lilly uses Big Pharma heft to lift up-and-coming biotechs",
      "id": 137740094,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "With great power comes great responsibility, and Eli Lilly is employing financial success and technical know-how to give smaller biotechs a leg up.",
      "url": "https://finnhub.io/api/news?id=7a6084352316af490fdd6bb1f536884386918294b9cc5d759164bb8ded481e0f"
    }
  },
  {
    "ts": null,
    "headline": "Mounjaro In China: Assessing Market Potential And Risks",
    "summary": "Mounjaro In China: Assessing Market Potential And Risks",
    "url": "https://finnhub.io/api/news?id=b8897586304dcfc3a8994b29aa71feaf6023d7d7040d15f9e0760a3cac34dcb7",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765264658,
      "headline": "Mounjaro In China: Assessing Market Potential And Risks",
      "id": 137739378,
      "image": "",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=b8897586304dcfc3a8994b29aa71feaf6023d7d7040d15f9e0760a3cac34dcb7"
    }
  },
  {
    "ts": null,
    "headline": "2 Potential Stock Splits to Watch for in 2026",
    "summary": "After experiencing incredible rallies during 2025, these two stocks could decide to \"split it\" in 2026.",
    "url": "https://finnhub.io/api/news?id=a3a0538c82a1b28d652c6acd410c14e646889b561a9ea5c83fa26dd834237341",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765258620,
      "headline": "2 Potential Stock Splits to Watch for in 2026",
      "id": 137737707,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "After experiencing incredible rallies during 2025, these two stocks could decide to \"split it\" in 2026.",
      "url": "https://finnhub.io/api/news?id=a3a0538c82a1b28d652c6acd410c14e646889b561a9ea5c83fa26dd834237341"
    }
  },
  {
    "ts": null,
    "headline": "Using Quantitative Signal Data For Portfolio Management",
    "summary": "One question weâve been asked many times is whether ValuEngine stock ratings can be used for portfolio management or merely for trading stocks.",
    "url": "https://finnhub.io/api/news?id=0e9697e80a4d66d511283dcf20467a67b49ea7bcf5972e4e457e9cf8608de118",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765254000,
      "headline": "Using Quantitative Signal Data For Portfolio Management",
      "id": 137738704,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2022152397/image_2022152397.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "One question weâve been asked many times is whether ValuEngine stock ratings can be used for portfolio management or merely for trading stocks.",
      "url": "https://finnhub.io/api/news?id=0e9697e80a4d66d511283dcf20467a67b49ea7bcf5972e4e457e9cf8608de118"
    }
  },
  {
    "ts": null,
    "headline": "Review Preview: Fed Jitters",
    "summary": "The Fed is expected to cut rates another quarter point on Wednesday. The question is what comes next.",
    "url": "https://finnhub.io/api/news?id=36d3dd559da366cc797fb7c209ea5d970a0c32a5798612445344264acb3ef288",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765241700,
      "headline": "Review Preview: Fed Jitters",
      "id": 137737708,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The Fed is expected to cut rates another quarter point on Wednesday. The question is what comes next.",
      "url": "https://finnhub.io/api/news?id=36d3dd559da366cc797fb7c209ea5d970a0c32a5798612445344264acb3ef288"
    }
  }
]